Snapshot from Jun 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Regencell Bioscience Holdings Faces...
Regulatory class action lawsuit

Regencell Bioscience Holdings Faces Class Actions

Analysis based on 23 articles · First reported Apr 25, 2026 · Last updated Jun 10, 2026

Sentiment
-50
Attention
4
Articles
23
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuits and the United States — United States Department of Justice investigation against Regencell Bioscience Holdings are expected to negatively impact the company's stock price and reputation. Investors who purchased Regencell Bioscience Holdings securities during the Class Period may suffer financial losses, while the involved law firms aim to recover damages for them.

biotechnology legal services
Event Summary

Multiple investor rights law firms, including Rosen Law Firm, Bronstein, Gewirtz & Grossman, LLC, and Robbins LLP, have filed class action lawsuits against Regencell Bioscience Holdings. These lawsuits allege that Regencell Bioscience Holdings and its officers made materially false and misleading statements between October 28, 2024, and October 31, 2025, regarding the company's business, operations, and compliance policies. Specifically, the complaints claim that Regencell Bioscience Holdings was vulnerable to market manipulation, which exposed investors to significant financial risk and subjected the company to heightened regulatory scrutiny and reputational harm. The United States — United States Department of Justice is also conducting an investigation into the trading of Regencell Bioscience Holdings' ordinary shares, requesting documents and communications. The company's stock price fell following the disclosure of this investigation. Investors have until June 23, 2026, to request to be appointed as lead plaintiff in these class actions.

Key Actions
100 Rosen Law Firm announces class action lawsuit Regencell Bioscience Holdings
95 United States — United States Department of Justice conducted investigation into Regencell Bioscience Holdings
90 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Regencell Bioscience Holdings
87 Regencell Bioscience Holdings disclosed investigation
85 Robbins LLP filed class action lawsuit Regencell Bioscience Holdings
Entities Involved
stock
Regencell Bioscience Holdings
Regencell Bioscience Holdings is the target of multiple class action lawsuits alleging securities fraud due to market manipulation and undisclosed risks, leading to significant financial and reputational harm. The company's stock price fell following the disclosure of a DOJ investigation.
Importance 100 Sentiment -75
govactor
United States — United States Department of Justice
The United States — United States Department of Justice is conducting an investigation into the trading of Regencell Bioscience Holdings' ordinary shares, indicating potential regulatory scrutiny and enforcement action.
Importance 85 Sentiment 0
priv
Rosen Law Firm
Rosen Law Firm is actively encouraging investors to join a class action lawsuit against Regencell Bioscience Holdings, seeking to recover damages for alleged securities fraud. The firm is a key player in initiating and leading this litigation.
Importance 80 Sentiment 45
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regencell Bioscience Holdings, alleging violations of federal securities laws due to market manipulation and misleading statements.
Importance 75 Sentiment 45
priv
Robbins LLP
Robbins LLP is investigating allegations that Regencell Bioscience Holdings was impacted by a stock manipulation scheme and has filed a class action lawsuit on behalf of investors.
Importance 70 Sentiment 40
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is a contact person for investors interested in joining the class action lawsuit against Regencell Bioscience Holdings.
Importance 60 Sentiment 40
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is highlighted for his firm's role in securities fraud class actions and for restoring investor capital.
Importance 60 Sentiment 40
per
Peretz Bronstein
Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, emphasizes the firm's commitment to restoring investor capital and ensuring corporate accountability in the Regencell Bioscience Holdings lawsuit.
Importance 55 Sentiment 40
per
Nathan Miller
Nathan Miller is the Client Relations Manager for Bronstein, Gewirtz & Grossman, LLC and a contact for investors regarding the Regencell Bioscience Holdings class action.
Importance 40 Sentiment 35
per
Aaron Dumas, Jr.
Aaron Dumas, Jr. is an attorney at Robbins LLP and a contact for shareholders regarding the class action lawsuit against Regencell Bioscience Holdings.
Importance 40 Sentiment 35
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.